Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: Long-term Daclizumab in RRMS
NCT01797965Phase 3Terminated
- Sponsor
- Biogen
- Start
- Feb 2013
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Feb 2013; status: terminated.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01797965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797965.